Vaccine protects from deadly Hendra virus

CSIRO's high bio-containment facility at the Australian Animal Health Laboratory was necessary to safely asses the vaccine’s effectiveness. Image credit - CSIRO

(Medical Xpress) -- CSIRO scientists have shown that a new experimental vaccine helps to protect horses against the deadly Hendra virus.

Dr Deborah Middleton from CSIRO’s Australian Animal Health Laboratory (AAHL) will announce the successful progress to develop the at the Australian Veterinary Association conference in Adelaide today.

“Our trials so far have shown that the vaccine prevents the infection of horses with Hendra virus,” Dr Middleton said.

Stopping the disease in horses could also help protect people from the disease.

“A horse vaccine is crucial to breaking the cycle of Hendra virus transmission from flying foxes to horses and then to people, as it prevents both the horse developing the disease and passing it on,” Dr Middleton said.

first appeared in 1994 and five of the 14 known outbreaks have spread to people. The virus has killed four of the seven people infected.

Depending on further development, field trials and registration the vaccine may be available as early as 2012.

Dr Barry Smyth, President of the Australian Veterinary Association, said that the news on the vaccine will be welcomed by both vets and horse owners.

“It’s important that veterinarians and horse owners continue with precautions that reduce the risk of spreading the virus and that they report suspected cases immediately,” Dr Smyth said.

Recent work on evaluating the vaccine was jointly funded by the CSIRO, the Australian Government Department of Agriculture, Fisheries and Forestry and the Queensland Government Department of Employment, Economic Development and Innovation.

The development of the vaccine goes back more than ten years to shortly after CSIRO scientists first isolated the following the first outbreak of the disease in Hendra, Queensland.

Development and source of the vaccine is the result of a close collaboration with Dr Christopher Broder of the Uniformed Services University of the Health Sciences (the US federal health sciences university) supported by the US National Institutes of Health, but the high bio-containment facility at AAHL was essential for evaluating its beneficial effects.

“Our bio-security facility at AAHL is the only laboratory in the world where this work could have been done. It has been slow, painstaking and high-risk work and the credit is due to many people who’ve worked on this since 1994,” Dr Middleton said.

Related Stories

Minimising the spread of deadly Hendra virus

Mar 31, 2009

(PhysOrg.com) -- CSIRO Livestock Industries' scientists working at the Australian Animal Health Laboratory (AAHL), in Geelong Victoria, have made a major breakthrough in better understanding how Hendra spreads ...

Scientists Develop Vaccine Against Deadly Viruses

Oct 04, 2006

Scientists from the Uniformed Services University of the Health Sciences (USU), in collaboration with counterparts from the Australian Animal Health Laboratory (AAHL), have developed a vaccine to fight two deadly animal viruses ...

Breakthrough in fight against Hendra virus

Oct 30, 2009

(PhysOrg.com) -- There has been a breakthrough in the fight against the deadly Hendra virus following the development of a treatment which shows great potential to save the lives of people who become infected ...

Australia uses experimental drug to halt virus spread

Jun 01, 2010

An experimental drug so far only tested on animals has been given to an Australian woman and child in an effort to prevent an outbreak of a potentially deadly virus, health officials said Tuesday.

Recommended for you

Determine patient preferences by means of conjoint analysis

13 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments